Stay updated on Immunotherapy for Anal Canal Cancer Clinical Trial
Sign up to get notified when there's something new on the Immunotherapy for Anal Canal Cancer Clinical Trial page.

Latest updates to the Immunotherapy for Anal Canal Cancer Clinical Trial page
- CheckyesterdayChange DetectedThe study record’s submission and posting dates advanced from November 11–13 to November 17–18, 2026, and the site revision changed from v3.8.0 to v3.8.1.SummaryDifference0.1%

- Check8 days agoChange DetectedThe study record’s update dates changed from September 2026 to November 2026, reflecting a more recent submission and posting.SummaryDifference0.1%

- Check15 days agoChange DetectedThe record now presents details for a phase II study of nivolumab with or without ipilimumab for refractory metastatic anal canal cancer, including eligibility, treatment arms, outcomes, and study locations. It also includes posted results and study documents.SummaryDifference100%

- Check22 days agoChange DetectedThe footer now identifies the site revision as v3.8.0 instead of v3.7.2, while the study page remains an error page.SummaryDifference0.2%

- Check29 days agoChange DetectedA sitewide NIH banner announces a transition in terminology from “Artificial Intelligence” to “Super Intelligence.” The study page itself continues to show a 403 Forbidden error.SummaryDifference1%

- Check36 days agoChange DetectedThe footer revision label changed from v3.7.1 to v3.7.2 while the page continued to display a 403 Forbidden error.SummaryDifference0.2%

Stay in the know with updates to Immunotherapy for Anal Canal Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Immunotherapy for Anal Canal Cancer Clinical Trial page.